---
title: "Huakang Clean: Abnormal fluctuations in stock trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250970709.md"
description: "Huakang Clean announced that its stock price deviation exceeded 30% over three consecutive trading days from July 29 to 31, 2025, which constitutes an abnormal fluctuation. After self-examination, the company found no undisclosed information that would have a significant impact on the stock trading price, and there have been no significant changes in the operating conditions and external environment. The controlling shareholder and actual controller have not disclosed any significant matters or stock trading activities"
datetime: "2025-07-31T10:40:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250970709.md)
  - [en](https://longbridge.com/en/news/250970709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250970709.md)
generator: "portal-rs"
---

# Huakang Clean: Abnormal fluctuations in stock trading

Huakang Clean announced that the closing price deviation of the company's stock exceeded 30% cumulatively over three consecutive trading days on July 29, 2025, July 30, 2025, and July 31, 2025, which constitutes an abnormal fluctuation in stock trading. The company conducted a self-examination and verification, finding that recent public media had not reported any undisclosed significant information that may have had a substantial impact on the trading price of the company's stock. The company's current operating conditions and internal and external operating environment have not undergone significant changes, and there are no major matters that should have been disclosed but were not by the controlling shareholder and actual controller. During the period of abnormal stock fluctuation, the controlling shareholder and actual controller did not engage in buying or selling the company's stock

### Related Stocks

- [301235.CN](https://longbridge.com/en/quote/301235.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario](https://longbridge.com/en/news/298196420.md)
- [Cyclezyme to buy Ragn-Sells melanin patent, pays via shares for 7.9% stake](https://longbridge.com/en/news/298137821.md)
- [Anker announces its first over-the-counter hearing aids](https://longbridge.com/en/news/297876505.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**